**Rademikibart Add-on Treatment of an Acute COPD Exacerbation** This study is testing a new medicine, rademikibart, for adults with a sudden worsening of Chronic Obstructive Pulmonary Disease (COPD) and type 2 inflammation. **COPD** is a lung disease that makes it hard to breathe. **Type 2 inflammation** is a kind of swelling in the body. This study is in **Phase 2**, meaning researchers are still learning how well the medicine works and if it's safe. Participants will be randomly chosen to receive either the new medicine with their regular treatment or a fake medicine (placebo) with their regular treatment. To join, you must have been diagnosed with COPD for at least a year and have experienced an episode needing special medicine called systemic corticosteroids. You must also be a smoker or former smoker with a history of 10 pack-years (which means smoking one pack a day for ten years). **Key Points:** - **Trial Duration**: Participation involves multiple visits to a healthcare facility. - **Compensation**: Participants may receive compensation for their time and involvement. - **Risks**: There may be risks, such as side effects, but these will be monitored by healthcare professionals. To participate, ensure you meet all eligibility criteria and understand the potential risks and benefits.